← Home
The Peter Attia Drive · June 29, 2026 · 09:56

#398 ‒ AMA #86: GLP-1 RAs and muscle loss: new data, better questions, and how to preserve muscle during weight loss

Peter Attia
Show Notes

Peter Attia examines new research on GLP-1 receptor agonists like Ozempic and Wegovy, with a focus on muscle loss. He explains why early alarms about high lean mass loss were partly driven by misinterpretation of DEXA scans, which count water loss as lean mass. The episode stresses that functional outcomes—strength and physical performance—matter more than body composition numbers alone. Peter also discusses early signals on retatrutide, a triple agonist that may preserve muscle better, and outlines practical steps to protect muscle and bone during weight loss, including protein intake and resistance training.

This summary was generated from show notes and public descriptions, not from a full transcript review. Details may contain inaccuracies.

Canon

•
GLP-1 receptor agonists cause significant lean mass loss, but composition matters more than total weight3:45
Peter explains that while GLP-1 drugs lead to substantial weight loss, a notable portion can be lean mass, raising concerns about muscle and bone health.
ClaudeChatGPTGemini
•
Adequate protein intake is essential to preserve muscle during GLP-1 weight loss
Peter recommends that individuals on GLP-1 receptor agonists prioritize protein consumption to counteract the catabolic effects of rapid weight loss on skeletal muscle.
ClaudeChatGPTGemini
•
Resistance training is critical for maintaining muscle and bone during GLP-1 weight loss
Peter highlights that combining GLP-1 therapy with structured resistance exercise is the best way to preserve lean mass, strength, and bone density.
ClaudeChatGPTGemini

Novel

•
Retatrutide, a next-generation triple agonist, may preserve muscle mass better than current GLP-1s
Peter discusses early evidence on retatrutide, a GLP-1/GIP/glucagon receptor agonist, which in preliminary studies appears to cause relatively less lean mass loss compared to semaglutide or tirzepatide.
ClaudeChatGPTGemini

Highlights

•
DEXA scans overstate muscle loss because lean mass includes water, which shifts during GLP-1 therapy6:15
Peter details how DEXA measurements of lean mass can mislead because they encompass water weight, and GLP-1s often cause rapid fluid shifts that inflate apparent muscle loss.
ClaudeChatGPTGemini
•
Functional outcomes like strength and physical performance are more important than body composition metrics during weight loss
Peter emphasizes that the goal of weight loss should not be a scale or DEXA number; maintaining functional ability—strength, mobility, and vitality—is the true metric of success.
ClaudeChatGPTGemini
Was this useful?